Skip to main content

CHEST 2025 Sanofi | Regeneron | Oct 19, 2025 - Oct 22, 2025

Immunology

Sanofi is committed to advancing the science of immunology through our research and development of innovative therapies for patients with chronic, difficult-to-treat, inflammatory diseases.

Available rooms
1 of 1
  • Chronic Obstructive Pulmonary Disease

  • Asthma

    Asthma is predominately a chronic type 2 inflammatory disease. When uncontrolled, asthma is characterized by impaired lung function, severe exacerbations, recurrent symptoms, and poor quality of life.